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Thermal disease presents a major burden to individual patient morbidity, healthcare cost as 
well as to over all economy. Burns also also represent a significant per-patient utlilisation of 
finite healthcare resources. Secondary complications in these patients, such as multiple drug 
resistant organisms, may have a devastating effect. Laser surgery has recently come of age 
as an optimal tool in the secondary reconstruction of burn injury, that is able to 
simultaneously address significant sheet scar tightness, hypertrophic, atrophic, and keloid 
complications, pruritus, microstomia, ectropion, skin graft honeycombing, and improve 
range of movement whilst reducing the risk of infection to &lt;1%. Yet, cutaneous laser 
surgery is often underutilised due to the perceived concerns about the sustainability of a 
new service with relatively high startup cost. We present a dual methodology to explore this 
concern: an evidence-based background review of the last 5 years of current best evidence, 
and a 22-year cost-analysis comparison at an established, high volume UK Centre of 
reconstructive surgery. We report that fiscal viability for laser surgery services for secondary 
burn reconstruction is supported by: level 2 (one systematic review) level 4 evidence (2 
studies) and level 5 evidence (expert reports). Evidence over 22 years from an established 
super-regional NHS laser centre shows that introduction of this service led to sustained and 
substantial cost saving, producing excellent surgical results at a fraction of the cost of 
traditional surgery. Analysis of the potential dollar-effect of these advantages to the general 
population supports state investment in expertise and capital equipment as a medium to 
long-term cost saving strategy, which may also aid re-integrating patients into the workforce 
making a meaningful contribution to the economy. 
 
Summary 
Multidrug resistant surgical infection is a global threat to the practice of surgery. This work is 
the first to describe a characteristic spectrum of Gram-negative bacteria to infect burn 
wounds, establish a clinically viable mechanism for passive drug accumulation and “smart 
release” at any infected soft tissue site. This work subsequently established an entirely novel 
class of macromolecular antibiotics. 
Burn wound infections in different centres were traditionally thought to be caused by 
differing sets of organisms. However, our metanalysis of standardised bacterial incidence 
rates confirmed Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumanni, 
Enterobacter spp., Proteus spp. and Escherichia coli as characteristic Gram-negative burn 
wound pathogens (F (4,20)=1.1, p=0.3797; r 2 =9.84). We subsequently identified a common 
biochemical cascade instigated by these bacteria, Streptococcus and Staphylococcus aureus 
which is bradykinin-controlled, leading to local vascular permeability enhancement (VPE). 
The mechanism leads to accumulation of macromolecules around the site of infection. 
Conventional “small molecule” antibiotics cannot target specifically an infected area- 
distributing to unintended sites, facilitating toxicity. This work therefore utilised the 
mechanisms heretofore discussed in custom-designing a prototype polymer-antibiotic 
conjugate that allows targeting to, and controlled release at, an infected site. I employed the 
biodegradable, naturally-occurring polymer, dextrin, and a “last-line” antibiotic, colistin, as 
the first model combination. 
Colistin’s toxic multiple amine groups, were eliminated through the formation of peptide 
bonds, to dextrin, facilitating linkage whilst reducing toxicity. The colistin was therefore 
“masked” in transit to the target site through chemical bonding and the steric hindrance of a 
large dextrin chain. The reaction was feasible, predictable and reproducible (r 2 =0.96, p 
&lt;0.0001). 
Exposed to normal levels of amylase activity (≤100 IU/L), minimally modified low 
molecular weight dextrin, conjugated to colistin, exhibited an ideal “masking” profile. Ex 
vivo, this lead compound also rapidly “unmasked” at infected sites. The resulting bioactivity 
was comparable to the current clinical formulation of colistin (Colimycin) against a clinical 
library of MDR A. baumanii, K. pneumoniae and E. coli. However the compound suppressed 
bacterial growth fourfold longer than the equivalent dose of Colimycin (p&lt;0.05). 
An ex vivo (n=6) series of human infected burn wound fluid samples confirmed a 
significantly higher amylase activity around wounds than in plasma. Upon incubation, 
colistin was easily “unmasked” at the infected site, supporting the notion of locally-triggered, 
enzymatically-mediated unmasking. An in vivo (n=32) Sprague Dawley rat model reported 
optimisation of pharmacokinetic parameters (plasma half-life doubled, clearance decreased 6- 
fold). In contrast to colistin, no clinical toxicity was observed at the highest protocol dose. 
This study is the first to establish the pathogens responsible for the majority of Gram- 
negative burn wound infections. The EPR mechanism is dependent on human bradykinin 
release in response to non-specific bacterial infection; the accumulated amylase is human, 
emphasising the applicability of this proof of concept for target antibiotics to most soft tissue 
infections, achieving controlled release whilst minimising adverse effect. This approach 
provides an effective clinical tool for the treatment of surgical soft tissue infection. 
